Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer

BACKGROUND: Tyrosine kinase inhibitors (TKIs) have demonstrated clinical benefits in the treatment of several tumour types. However, the emergence of TKI resistance restricts the therapeutic effect. This study uses non-small cell lung cancer (NSCLC) to explore the mechanisms contributing to TKI resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Meng, Yang, Jingyu, Zhou, Wenlong, Ren, Yong, Wang, Xiaoxuan, Chen, Huiping, Zhang, Jingyuan, Chen, Junli, Sun, Yuhong, Cui, Lijuan, Liu, Xing, Wang, Lihui, Wu, Chunfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625681/
https://www.ncbi.nlm.nih.gov/pubmed/28850563
http://dx.doi.org/10.1038/bjc.2017.292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625681/
https://www.ncbi.nlm.nih.gov/pubmed/28850563
http://dx.doi.org/10.1038/bjc.2017.292

Ejemplares similares